查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1772229

全球胃癌诊断市场：市场规模、份额、趋势分析（按产品、疾病类型、最终用途和地区）、细分市场预测（2025-2033）

Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric lymphoma), By End Use, By Region And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

胃癌诊断市场概况

2024 年全球胃癌诊断市场规模估计为 11.8 亿美元，预计到 2033 年将达到 22.2 亿美元，2025 年至 2033 年的复合年增长率为 7.43%。胃癌发病率的上升、对早期检测和筛检计划的日益重视以及对个人化医疗的需求不断增长，正在推动市场成长。

胃癌是全球第五大常见癌症，其发生率的不断上升推动了对先进诊断工具的需求，并凸显了早期发现和改善患者预后的迫切需求。根据美国国家癌症研究所 (NIH) 的数据，预计到 2025 年，全球将新增约 30,300 例胃癌病例，并导致约 10,780 例胃癌死亡。

幽门螺旋桿菌感染、吸烟、高盐饮食和老龄化等因素都会加重胃癌的发病负担。胃癌死亡率随年龄增加而上升。 2019年和2023年的年龄调整死亡率均为每10万人每年2.7例（男性和女性）。下图显示了2019年至2022年各年龄层胃癌新病例的比例。

胃癌是全球癌症相关死亡的主要原因之一，因此对早期精准诊断工具的需求日益增长。医疗保健系统越来越重视筛检项目和早期检测，这推动了对内视镜检查、切片检查、影像技术和分子诊断的需求，显着扩大了传统和先进诊断解决方案的市场。

市场成长的另一个驱动力是世界各国政府和医疗机构正在实施的筛检计画的扩展，以便在早期、更可治疗的阶段发现高风险族群中的胃癌。例如，2025 年 4 月，美国国立卫生研究院 (NIH) 将在五年内向研究人员提供 260 万美元的资助，以领导一个由研究人员、临床医生和电脑科学家组成的国家团队，评估在美国进行胃癌筛检的可行性。日本和韩国等国家已经建立了包括内视镜检查在内的全国性筛检倡议，这已被证明可有效降低死亡率。随着类似计划扩展到其他地区，对准确且高效的诊断工具的需求正在增长。这种向预防肿瘤学和早期检测的转变是胃癌诊断行业发展的强大驱动力，尤其是在公共医疗系统寻求降低长期治疗成本的情况下。

个人化医疗的转变正在对胃癌诊断产业产生重大影响。基于生物标记的检测和基因组分析使临床医生能够根据患者的个别情况制定个人化治疗方案，从而改善治疗效果。这种精准方法依赖先进的诊断工具，例如次世代定序(NGS)、免疫组织化学和伴随诊断。随着标靶治疗的日益普及，对用于识别胃癌中 HER2、PD-L1、MSI 和其他生物标记的分子诊断的需求也日益增长。个人化医疗可以提高存活率，并提高治疗的成本效益，从而鼓励医疗保健提供者和付款方采用更先进的诊断平台。例如，在转移性胆道癌中，年轻患者的预后往往比老年患者更好，因为他们的肿瘤更有可能存在可操作的基因变异，而这些变异正是个人化治疗的候选对象。

生物标记能够在早期阶段检测出与癌症发展相关的分子和基因变化，这对于改善患者预后至关重要。生物标记，尤其是在血液和其他体液中发现的生物标记物，与内视镜检查和切片检查相比，可以提供非侵入性或微创性的检查选择，并减少患者的不适感。它们还能即时监测病情进展和疗效，促进个人化医疗。此外，生物标记有助于克服影像诊断的局限性，例如分辨率低和对操作者的依赖性，并以更高的灵敏度和特异性区分良性和恶性病变。因此，下文列出了生物标记在胃癌诊断中的新兴趋势。

目录

第一章 分析方法与范围

第二章执行摘要

3. 胃癌诊断市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 胃癌诊断市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析

第四章胃癌诊断市场：按产品分類的估计和趋势分析

  • 各产品市场占有率（2024 年及 2033 年）
  • 细分仪表板
  • 胃癌诊断市场：按产品分類的波动分析
  • 胃癌诊断市场规模及产品趋势分析（2021-2033）
  • 胃癌诊断市场：收益估计与预测（2021-2033）
  • 试剂和耗材
  • 装置

第五章胃癌诊断市场：依疾病类型估计与趋势分析

  • 按疾病类型分類的市场占有率（2024 年和 2033 年）
  • 细分仪表板
  • 胃癌诊断市场：依疾病类型波动分析
  • 市场规模预测与趋势分析（2021-2033）
  • 腺癌
  • 胃淋巴瘤
  • 其他的

第六章胃癌诊断市场：依最终用途的估计和趋势分析

  • 按最终用途分類的市场占有率（2024 年和 2033 年）
  • 细分仪表板
  • 胃癌诊断市场：依最终用途分類的差异分析
  • 市场规模预测与趋势分析（2021-2033）
  • 医院
  • 诊断实验室
  • 诊断影像

第七章胃癌诊断市场：按地区估计和趋势分析

  • 各地区市场占有率（2024 年及 2033 年）
  • 市场仪表板：按地区
  • 全球市场概况：按地区
  • 市场规模预测与趋势分析（2021-2033）
  • 北美洲
    • 北美：SWOT分析
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲：SWOT分析
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 亚太地区：SWOT分析
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中东和非洲
    • MEA：SWOT分析
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要企业近期趋势及影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 主要客户
    • 主要企业市场占有率分析（2024年）
    • MiRXES Pte Ltd.
    • Agilent Technologies Inc
    • Endofotonics Pte Ltd
    • Bio-Rad Laboratories, Inc
    • Hipro Biotechnology Co., Ltd
    • Exact Sciences Corporation
    • QIAGEN
    • Fulgent Genetics.
    • F. Hoffmann-La Roche Ltd
    • Abbott
Product Code: GVR-4-68040-648-2

Gastric Cancer Diagnostics Market Summary

The global gastric cancer diagnostics market was estimated at USD 1.18 billion in 2024 and is projected to reach USD 2.22 billion by 2033, growing at a CAGR of 7.43% from 2025 to 2033. The market is growing, driven by the rising incidence of gastric cancer, growing emphasis on early detection and screening programs, and escalating demand for personalized medicines.

Gastric cancer ranks as the 5th most common cancer worldwide, and its rising incidence drives the demand for advanced diagnostic tools, highlighting the urgent need for early detection and improved patient outcomes. According to the National Cancer Institute (NIH), in 2025, it is projected that there will be approximately 30,300 new stomach cancer cases, with about 10,780 deaths expected from the disease

Some of the factors, such as Helicobacter pylori infection, smoking, high-salt diets, and aging, are contributing to a higher disease burden. The mortality rate for gastric cancer rises as people get older. In 2019 and 2023, the age-adjusted death rate for both men and women was 2.7 per 100,000 individuals annually. The chart below illustrates the percentage of new cases (%) by age group of gastric cancer for the period 2019-2022

Gastric cancer, being one of the leading causes of cancer-related deaths worldwide, has led to a rising demand for its early, accurate diagnostic tools. Healthcare systems are placing greater emphasis on screening programs and early detection, which drives the need for endoscopy, biopsy, imaging technologies, and molecular diagnostics, significantly expanding the market for both conventional and advanced diagnostic solutions.

Another factor for market growth is growing screening programs that the governments and healthcare organizations worldwide are implementing to detect gastric cancer in high-risk populations at earlier, more treatable stages. For instance in April, 2025, National Institutes of Health (NIH) has awarded a researcher USD 2.6 million over five years to lead a national team of researchers, clinicians, and computer scientists in evaluating the feasibility of gastric cancer screening in the U.S. Early detection significantly improves survival rates, prompting increased investments in diagnostic infrastructure. Countries like Japan and South Korea have established nationwide screening initiatives that include endoscopic examinations, which have proven effective in reducing mortality. As similar programs expand to other regions, the need for accurate and efficient diagnostic tools grows. This push toward preventive oncology and early-stage detection is a powerful driver of the gastric cancer diagnostics industry, especially as public health systems seek to reduce long-term treatment costs.

The shift toward personalized medicine is significantly influencing the gastric cancer diagnostics industry. Biomarker-based tests and genomic profiling allow clinicians to tailor treatments to individual patient profiles, improving therapeutic outcomes. This precision approach relies on advanced diagnostic tools such as next-generation sequencing (NGS), immunohistochemistry, and companion diagnostics. As targeted therapies become more prevalent, the need for molecular diagnostics to identify HER2, PD-L1, MSI, and other biomarkers in gastric cancer grows. Personalized medicine improves survival and enhances the cost-effectiveness of care, encouraging both healthcare providers and payers to adopt more advanced diagnostic platforms. For example, in metastatic biliary tract cancers, younger individuals tended to have a better prognosis than older patients, because their tumors were more likely to contain actionable genetic alterations that made them suitable candidates for personalized treatments.

Biomarkers can detect earlier molecular and genetic changes associated with cancer development, which is crucial for improving patient outcomes. Biomarkers, especially those found in blood or other body fluids, provide non-invasive or minimally invasive options, reducing patient discomfort compared to endoscopy or biopsy. They also allow for real-time monitoring of disease progression and treatment response, facilitating personalized medicine. Moreover, biomarkers can help differentiate between benign and malignant lesions with higher sensitivity and specificity, overcoming limitations of imaging such as low resolution or operator dependency. Hence, some emerging trends in biomarkers for gastric cancer diagnostics are listed below.

Global Gastric Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global gastric cancer diagnostics market report based on product, disease type, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Reagents & Consumables
  • Instruments
  • Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Adenocarcinoma
  • Gastric lymphoma
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Diagnostic Imaging
  • Regional Outlook (Revenue in USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease Type
    • 1.2.3. End use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Disease type outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Gastric Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Gastric Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Gastric Cancer Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Gastric Cancer Diagnostics Market: Product Movement Analysis
  • 4.4. Gastric Cancer Diagnostics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.5. Gastric Cancer Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Reagents & consumables
    • 4.6.1. Reagents & consumables Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Instruments
    • 4.7.1. Instruments Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Gastric Cancer Diagnostics Market: Disease Type Estimates & Trend Analysis

  • 5.1. Disease Type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Gastric Cancer Diagnostics Market by Disease Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Adenocarcinoma
    • 5.5.1. Adenocarcinoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Gastric lymphoma
    • 5.6.1. Gastric Lymphoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Gastric Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Gastric Cancer Diagnostics Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Hospitals
    • 6.5.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Diagnostic Imaging
    • 6.7.1. Diagnostic Imaging Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Gastric Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts, Trend Analysis, 2021 to 2033:
  • 7.5. North America
    • 7.5.1. North America: SWOT Analysis
    • 7.5.2. U.S.
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/Reimbursement
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. Canada
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/Reimbursement
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/Reimbursement
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. Europe: SWOT Analysis
    • 7.6.2. UK
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/Reimbursement
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. Germany
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/Reimbursement
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/Reimbursement
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/Reimbursement
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Spain
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/Reimbursement
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.7. Norway
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/Reimbursement
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.8. Sweden
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/Reimbursement
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.9. Denmark
      • 7.6.9.1. Key country dynamics
      • 7.6.9.2. Regulatory framework/Reimbursement
      • 7.6.9.3. Competitive scenario
      • 7.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Asia Pacific: SWOT Analysis
    • 7.7.2. Japan
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/Reimbursement
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. China
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/Reimbursement
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. India
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/Reimbursement
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.5. Australia
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/Reimbursement
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.6. South Korea
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/Reimbursement
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.7. Thailand
      • 7.7.7.1. Key country dynamics
      • 7.7.7.2. Regulatory framework/Reimbursement
      • 7.7.7.3. Competitive scenario
      • 7.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Latin America: SWOT Analysis
    • 7.8.2. Brazil
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/Reimbursement
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/Reimbursement
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. MEA: SWOT Analysis
    • 7.9.2. South Africa
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/Reimbursement
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/Reimbursement
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/Reimbursement
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key country dynamics
      • 7.9.5.2. Regulatory framework
      • 7.9.5.3. Competitive scenario
      • 7.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. MiRXES Pte Ltd.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Agilent Technologies Inc
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Endofotonics Pte Ltd
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Bio-Rad Laboratories, Inc
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Hipro Biotechnology Co., Ltd
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Exact Sciences Corporation
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. QIAGEN
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Fulgent Genetics.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. F. Hoffmann-La Roche Ltd
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Abbott
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Gastric Cancer Diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 4 North America Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 5 North America Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 6 U.S Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 7 U.S Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 8 U.S Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 9 Canada Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 10 Canada Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 11 Canada Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 12 Mexico Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 13 Mexico Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Europe Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 16 Europe Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 17 Europe Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 18 UK Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 19 UK Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 20 UK Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 21 Germany Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 22 Germany Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 23 Germany Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 24 France Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 25 France Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 26 France Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 27 Italy Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 28 Italy Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 29 Italy Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 30 Spain Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 31 Spain Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 32 Spain Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 33 Denmark Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 34 Denmark Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 35 Denmark Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 36 Sweden Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 37 Sweden Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 38 Sweden Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 39 Norway Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 40 Norway Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 41 Norway Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 42 Asia Pacific Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 45 Japan Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 46 Japan Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 47 Japan Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 48 China Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 49 China Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 50 China Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 51 India Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 52 India Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 53 India Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 54 Australia Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 55 Australia Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 56 Australia Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 57 South Korea Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 58 South Korea Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 59 South Korea Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 60 Thailand Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 61 Thailand Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 62 Thailand Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 63 Latin America Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 64 Latin America Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 65 Latin America Gastric Cancer Diagnostics market, by end use 2021 - 2033 (USD Million)
  • Table 66 Brazil Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 67 Brazil Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 68 Brazil Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 69 Argentina Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 70 Argentina Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 71 Argentina Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 72 MEA Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 73 MEA Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 74 MEA Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 75 South Africa Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 76 South Africa Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 77 South Africa Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 78 Saudi Arabia Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 79 Saudi Arabia Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 80 Saudi Arabia Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 81 UAE Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 82 UAE Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 83 UAE Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 84 Kuwait Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 85 Kuwait Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 86 Kuwait Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Gastric Cancer Diagnostics market: market outlook
  • Fig. 14 Gastric Cancer Diagnostics Competitive Insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Gastric Cancer Diagnostics Market Driver Impact
  • Fig. 20 Gastric Cancer Diagnostics Market Restraint Impact
  • Fig. 21 Gastric Cancer Diagnostics Market Strategic Initiatives Analysis
  • Fig. 22 Gastric Cancer Diagnostics market: Product movement analysis
  • Fig. 23 Gastric Cancer Diagnostics market: Product outlook and key takeaways
  • Fig. 24 Reagents & consumables market estimates and forecasts, 2021 - 2033
  • Fig. 25 Instruments market estimates and forecasts,2021 - 2033
  • Fig. 26 Gastric Cancer Diagnostics Market: Disease Type Movement Analysis
  • Fig. 27 Gastric Cancer Diagnostics market: Disease type outlook and key takeaways
  • Fig. 28 Adenocarcinoma market estimates and forecasts, 2021 - 2033
  • Fig. 29 Gastric lymphoma market estimates and forecasts, 2021 - 2033
  • Fig. 30 Other market estimates and forecasts, 2021 - 2033
  • Fig. 31 Gastric Cancer Diagnostics Market: End use movement analysis
  • Fig. 32 Gastric Cancer Diagnostics market: End use outlook and key takeaways
  • Fig. 33 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 34 Diagnostic Laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 35 Diagnostic Imaging market estimates and forecasts, 2021 - 2033
  • Fig. 36 Global Gastric Cancer Diagnostics market: Regional movement analysis
  • Fig. 37 Global Gastric Cancer Diagnostics market: Regional outlook and key takeaways
  • Fig. 38 Global Gastric Cancer Diagnostics market share and leading players
  • Fig. 39 North America market share and leading players
  • Fig. 40 Europe market share and leading players
  • Fig. 41 Asia Pacific market share and leading players
  • Fig. 42 Latin America market share and leading players
  • Fig. 43 Middle East & Africa market share and leading players
  • Fig. 44 North America, by country
  • Fig. 45 North America
  • Fig. 46 North America market estimates and forecasts, 2021 - 2033
  • Fig. 47 U.S.
  • Fig. 48 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 49 Canada
  • Fig. 50 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 51 Mexico
  • Fig. 52 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 53 Europe
  • Fig. 54 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 55 UK
  • Fig. 56 UK market estimates and forecasts, 2021 - 2033
  • Fig. 57 Germany
  • Fig. 58 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 59 France
  • Fig. 60 France market estimates and forecasts, 2021 - 2033
  • Fig. 61 Italy
  • Fig. 62 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 63 Spain
  • Fig. 64 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 65 Denmark
  • Fig. 66 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 67 Sweden
  • Fig. 68 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 69 Norway
  • Fig. 70 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 71 Asia Pacific
  • Fig. 72 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 73 China
  • Fig. 74 China market estimates and forecasts, 2021 - 2033
  • Fig. 75 Japan
  • Fig. 76 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 77 India
  • Fig. 78 India market estimates and forecasts, 2021 - 2033
  • Fig. 79 Thailand
  • Fig. 80 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 81 South Korea
  • Fig. 82 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 83 Australia
  • Fig. 84 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 85 Latin America
  • Fig. 86 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 87 Brazil
  • Fig. 88 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 89 Argentina
  • Fig. 90 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 91 Middle East and Africa
  • Fig. 92 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 93 South Africa
  • Fig. 94 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 95 Saudi Arabia
  • Fig. 96 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 97 UAE
  • Fig. 98 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 99 Kuwait
  • Fig. 100 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 101 Market share of key market players- Gastric Cancer Diagnostics market